scholarly journals Exercise and Garlic Modulate microRNAs Involved in Diabetic Cardiopathy

2018 ◽  
Author(s):  
Aline Regina Ruiz Lima
Keyword(s):  
Diabetic Cardiopathy

scholarly journals Salvianolic Acid B Attenuates Apoptosis of HUVEC Cells Treated with High Glucose or High Fat via Sirt1 Activation

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Jinghui Zhai ◽  
Lina Tao ◽  
Yueming Zhang ◽  
Huan Gao ◽  
Xiaoyu Qu ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
High Glucose ◽  
Molecular Mechanisms ◽  
Umbilical Vein ◽  
Salvianolic Acid B ◽  
Sirtuin 1 ◽  
High Fat ◽  
Salvianolic Acid ◽  
Huvec Cells ◽  
Diabetic Cardiopathy

High glucose and high fat are important inducements for the development and progression of diabetic cardiopathy. Salvianolic acid B (SAB), which is the most abundant and bioactive compound in Danshen, attenuates oxidative stress-related disorders, such as cardiovascular diseases, cerebral ischemia, and diabetes. However, the effect of SAB on diabetic cardiopathy is not clear. The aim of study was to investigate the effect and the underlying molecular mechanisms of SAB on diabetic cardiopathy in vitro model. The human umbilical vein endothelial (HUVEC) cells were treated with high glucose (HG, 30 mM) or high fat (palmitic acid, PA, 0.75 mM) in the presence or absence of SAB (100, 200, and 400 mg/L) and incubated for 24 h. We found that HG or PA induced apoptosis of HUVEC cells, while treatment with SAB inhibited the apoptosis. We also found that SAB reversed HG- or PA-induced oxidative stress, apoptosis cell cytokines production, and expression of thioredoxin-interacting protein (TXNIP). Moreover, SAB increased HG- or PA-induced expression of Sirtuin 1 (Sirt1), a nicotinamide adenine dinucleotide- (NAD+-) dependent histone deacetylase. Exposure of HUVEC cells to Ex527 (Sirt1 inhibitor) suppressed the effect of SAB on acetyl-p53 and procaspase-3 expressions. In conclusion, the results suggested that SAB could attenuate HUVEC cells damage treated with HG or PA via Sirt1 and might be a potential therapy agent for the diabetic cardiopathy treatment.

scholarly journals New Insights for BPIFB4 in Cardiovascular Therapy

2020 ◽  
Vol 21 (19) ◽  
pp. 7163 ◽  
Author(s):  
Marta Dossena ◽  
Anna Ferrario ◽  
Valentina Lopardo ◽  
Elena Ciaglia ◽  
Annibale Alessandro Puca
Keyword(s):  
Immune System ◽  
Therapeutic Effects ◽  
Industrialized Countries ◽  
Age Related ◽  
Cardiovascular Therapy ◽  
Relevant Risk Factor ◽  
Oxide Synthase ◽  
Endothelial Nitric Oxide ◽  
Shed Light ◽  
Diabetic Cardiopathy

Aging is the most relevant risk factor for cardiovascular diseases which are the main cause of mortality in industrialized countries. In this context, there is a progressive loss of cardiovascular homeostasis that translates in illness and death. The study of long living individuals (LLIs), which show compression of morbidity toward the end of their life, is a valuable approach to find the key to delay aging and postpone associate cardiovascular events. A contribution to the age-related decline of cardiovascular system (CVS) comes from the immune system; indeed, it is dysfunctional during aging, a process described as immunosenescence and comprises the combination of several processes overpowering both innate and adaptative immune system. We have recently discovered a longevity-associated variant (LAV) in bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4), which is a secreted protein able to enhance endothelial function through endothelial nitric oxide synthase (eNOS) activation and capable to protect from hypertension, atherosclerosis, diabetic cardiopathy, frailty, and inflammaging. Here, we sum up the state of the art of the mechanisms involved in the main pathological processes related to CVD (atherosclerosis, aging, diabetic cardiopathy, and frailty) and shed light on the therapeutic effects of LAV-BPIFB4 in these contexts.

scholarly journals Diabetic cardiopathy

Diabetologia ◽  
1979 ◽  
Vol 16 (4) ◽  
pp. 207-209 ◽  
Author(s):  
T. Ledet ◽  
B. Neubauer ◽  
N. J. Christensen ◽  
K. Lundb�k
Keyword(s):  
Diabetic Cardiopathy

Diabetic cardiopathy: Is it a real entity?

1988 ◽  
Vol 4 (3) ◽  
pp. 273-288 ◽  
Author(s):  
G. Crepaldi ◽  
R. Nosadini
Keyword(s):  
Real Entity ◽  
Diabetic Cardiopathy

Cardioprotective mechanisms of the kallikrein–kinin system in diabetic cardiopathy

2006 ◽  
Vol 15 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Frank Spillmann ◽  
Sophie Van Linthout ◽  
Heinz-Peter Schultheiss ◽  
Carsten Tschöpe
Keyword(s):  
Kinin System ◽  
Kallikrein Kinin System ◽  
Diabetic Cardiopathy
Sign in / Sign up

Export Citation Format

Share Document